NCT05483933 2025-12-23Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersShattuck Labs, Inc.Phase 1 Completed86 enrolled 17 charts
NCT01004380 2014-07-17Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian CancerMorphotekPhase 1 Completed15 enrolled